Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment

Giulia Giacomucci,Salvatore Mazzeo,Assunta Ingannato,Chiara Crucitti,Silvia Bagnoli,Sonia Padiglioni,Lucrezia Romano,Giulia Galdo,Filippo Emiliani,Daniele Frigerio,Camilla Ferrari,Valentina Moschini,Carmen Morinelli,Antonella Notarelli,Sandro Sorbi,Benedetta Nacmias,Valentina Bessi
DOI: https://doi.org/10.1038/s41598-024-61655-6
IF: 4.6
2024-05-18
Scientific Reports
Abstract:We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer's Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP−) when they were A−, A+/T−/N−, or A+/T−/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP− patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn's k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to evaluate the diagnostic accuracy of plasma phosphorylated tau protein 181 (p - tau181) and neurofilament light chain protein (NfL) used alone and in combination to distinguish patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) with Alzheimer's disease (AD) pathological features from non - carriers. In addition, the study also proposes a flowchart for interpreting the results of plasma p - tau181 and NfL for the detection in the early stage of cognitive decline, and explores the potential of these biomarkers in future clinical applications. Specifically, the main objectives of the study include: 1. **Evaluating diagnostic accuracy**: Evaluate the diagnostic accuracy of plasma p - tau181 and NfL respectively, as well as their combined diagnostic accuracy, to distinguish SCD and MCI patients with AD pathological features from non - carriers. 2. **Exploring consistency**: Study the consistency between the results of plasma p - tau181 and NfL. 3. **Proposing an interpretation flowchart**: Based on the research results, propose a flowchart for interpreting the results of plasma p - tau181 and NfL in order to detect AD pathological features in the early stage of cognitive decline. 4. **Risk estimation**: Estimate the impact of positive or negative plasma p - tau181 and NfL on the risk of AD pathological features through a logistic regression model. The research background points out that although the currently commonly used AD biomarkers (such as cerebrospinal fluid biomarkers, PET neuroimaging and brain MRI) are very accurate in the early detection of AD pathological features, their application in large - scale populations is limited by cost, accessibility and invasiveness. Therefore, the search for more accessible biomarkers, such as those in the blood, has become the focus of research. Plasma p - tau181 and NfL have shown high accuracy in the early detection of AD, but their application in clinical practice is still limited, and it is not clear how to interpret the results of combined use. Therefore, this study attempts to fill this gap.